The mucosal immune system of the upper respiratory tract and recent progress in mucosal vaccines.


Journal

Auris, nasus, larynx
ISSN: 1879-1476
Titre abrégé: Auris Nasus Larynx
Pays: Netherlands
ID NLM: 7708170

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 05 06 2021
accepted: 06 07 2021
pubmed: 27 7 2021
medline: 8 3 2022
entrez: 26 7 2021
Statut: ppublish

Résumé

The mucosal immune system prevents microorganism invasion through mucosal surfaces and consists of inductive and effector sites. Nasopharynx-associated lymphoid tissue (NALT) functions as an inductive site, inducing mucosal immune responses in the upper respiratory tract. It follows that intranasal vaccines may prevent upper respiratory infections. To induce and enhance the immune response by administering inactivated antigens intranasally, mucosal adjuvants have been developed, including mutant cholera toxin and cationic cholesteryl pullulan nanogel, which do not accumulate in the central nervous system. Moreover, multivalent pneumococcal polysaccharide conjugate vaccines are used to prevent invasive pneumococcal infections and otitis media, although they only provide moderate protection against acute otitis media because non-vaccine serotypes of Streptococcus pneumoniae and Haemophilus influenzae also cause this infection. To address this problem, pneumococcal surface protein A of S. pneumoniae and P6 of H. influenzae are used as broad-spectrum vaccine antigens. Alternatively, phosphorylcholine (PC) is present in the cell walls of both gram-positive and gram-negative bacteria and induces immune responses through antigenic activity. The significant effects of PC as a mucosal vaccine have been demonstrated through intranasal and sublingual immunization in mice. Furthermore, intranasal administration of PC reverses increases in IgE levels and prevents allergic rhinitis. After immunization with pneumococcal polysaccharide conjugate vaccine, intranasal immunization with PC boosts immune responses to vaccine strains and to PC itself. Thus, PC may be useful as a mucosal vaccine to prevent upper respiratory infections and allergic rhinitis, and it could be used as a booster to the currently used pneumococcal vaccine as it protects against non-vaccine strains.

Identifiants

pubmed: 34304944
pii: S0385-8146(21)00195-4
doi: 10.1016/j.anl.2021.07.003
pii:
doi:

Substances chimiques

Antigens, Bacterial 0
Immunoglobulin A, Secretory 0
Pneumococcal Vaccines 0
Vaccines 0
Phosphorylcholine 107-73-3

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-10

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Auteurs

Yuichi Kurono (Y)

Department of Otolaryngology, Head and Neck Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan. Electronic address: k1267943@kadai.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH